‘Image and treat’: an individualized approach to urological tumors
- 1 May 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Oncology
- Vol. 22 (3), 274-280
- https://doi.org/10.1097/cco.0b013e3283373d5c
Abstract
Purpose of review The current treatment options for advanced urologic cancers demonstrate limited efficacy. To obtain optimal clinical results, there is a need for new, individualized, therapeutic strategies, which have only recently been applied to these malignancies. Nuclear medicine plays an important role in establishing imaging biomarkers necessary for personalized medicine. This review focuses on the current status of the ‘image and treat’ approach combining molecular imaging with targeted radionuclide therapy of urological malignancies Recent findings Tumor-specific targets in uro-oncology are showing promising results for development of personalized therapy using positron emission tomography/computed tomography (PET/CT) molecular imaging and radioimmunotherapy. The antibody cG250, which binds to carbonic anhydrase IX, is being evaluated as a radiolabeled imaging and therapeutic agent in clear-cell renal cell carcinoma. 124I-cG250 PET/CT has demonstrated excellent targeting of clear-cell renal cell carcinoma. Prostate-specific membrane antigen is a promising target for both PET/CT and radioimmunotherapy of prostate cancer. HER2 may be another potential target in bladder and prostate cancer. Summary Tumor-specific targets and biomarkers are being studied for PET/CT and radioimmunotherapy. This may lead to development of new therapeutic strategies. However, considerable investment in new research will be required for personalized medicine to be routinely used in uro-oncology.Keywords
This publication has 75 references indexed in Scilit:
- Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patientsAnnals of Oncology, 2009
- Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancerCurrent Opinion in Oncology, 2009
- Imaging Localized Prostate Cancer: Current Approaches and New DevelopmentsAmerican Journal of Roentgenology, 2009
- Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate CancerJournal of Medicinal Chemistry, 2008
- Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)Journal of Medicinal Chemistry, 2008
- Prostate cancerThe Lancet, 2008
- N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate CancerClinical Cancer Research, 2008
- Antibody therapy in renal cell carcinomaWorld Journal of Urology, 2008
- [18F]FBEM-ZHER2:342-Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomographyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Radiolabeled antibodies in renal cell carcinomaCancer Imaging, 2007